Диссертация (Анализ применения фармакогенетического тестирования для индивидуализации применения пероральных антикоагулянтов и статинов у пациентов терапевтического профиля в условиях функционирования центра персонализированной медицины), страница 28

P., Garg A. X., Haynes R. B. Interventions to enhance patient adherenceto medication prescriptions: scientific review JAMA. 2002; 22(288):2868-2879.138. Mendez-Jandula B. et al. Comparing self-management of oral anticoagulation therapywith clinic management. Ann Intern Med.-2005; 142:1-10139. Meyer zu Schwabedissen HE, Albers M, Baumeister SE et al. Function-impairingpolymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacyof statins in a population-based cohort. Pharmacogenet Genomics.

2015 Jan;25(1):8-18140. Mhairi Copland «Oral Anticoagulation and Hemorrhagic Complications in an ElderlyPopulation With Atrial Fibrillation» Arch Inter Med 2001; 161:17141. Miao L. et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotypeto the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinesepatients //European journal of clinical pharmacology. 2007; 12(63):1135-1141.142. Mills E.J., Rachlis B., Wu P.

et al. Primary prevention of cardiovascular mortality andevents with statin treatments. A network meta-analysis involving more than 65,000 patients.J. Am. Coll. Cardiol. 2008; 52:1769–1781.142143. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor on serum coenzyme Q10 in diabeticpatients. Arzneimittelforschung 1999; 49:324-9.144. Morand OH, Aebi JD, Dehmlow H, et al. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, andminipigs: comparison to simvastatin. J Lipid Res 1997; 38:373-90.145.

Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzymeQ10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18:137-44.146. Naccarelli G., Varker H. Increasing prevalence of atrial fibrillation and flutter in theUnited States // Am. J. Cardiol. 2009.Vol. 104. Р. 1534–1539.147. Nakao K, Seto S, Ueyama C, et al. (October 2002). «Extended distribution ofprolonged and fractionated right atrial electrograms predicts development of chronic atrialfibrillation in patients with idiopathic paroxysmal atrial fibrillation».

J. Cardiovasc.Electrophysiol. 13 (10): 996–1002. PMID 12435185.148. Narumiya T, Sakamaki T, Sato Y, Kanmatsuse K. «Relationship between left atrialappendage function and left atrial thrombus in patients with nonvalvular chronic atrialfibrillation and atrial flutter». Circulation Journal 2003; 1(67): 68–72. PMID 12520155.149.

Nebert D. W. et al. Role of aryl hydrocarbon receptor-mediated induction of the CYP1enzymes in environmental toxicity and cancer //Journal of Biological Chemistry. 2004;23(279); 23847-23850.150. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy?An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007;29:1761-70151. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1:a genetically polymorphic transporter of major importance for hepatic drug uptake.Pharmacol Rev 2011; 63:157–181.152. Niemi, Mikko.

SLCO1B1 polymorphism markedly affects the pharmacokinetics ofsimvastatin acid// Pharmacogenetics and Genomics: December 2006; 12: 873-879143153. Nishizato Y., Ieiri I., Suzuki H., et al. Polymorphisms of OATP-C (SLC21A6) andOAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. ClinicalPharmacology & Therapeutics. 2003; 73 (6): 554–65. 5.154. Olesen J.

B. et al. Validation of risk stratification schemes for predicting stroke andthromboembolism in patients with atrial fibrillation: nationwide cohort study. Bmj. 2011;342:123-129155. Osterberg L., Blaschke T. Adherence to medication //New England Journal ofMedicine. 2005; 5(353):487-497.156. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL (January 1994).«Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation andparoxysmal supraventricular tachycardia».

Circulation. 1994; 89(1): 224–7. PMID8281651.157. Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal musclemetabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78:60-8.158. Palareti G. et al. on behalf of the Italian Study on Complications of Oral AnticoagulantTherapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort,prospective collaborative study (ISCOAT) Lancet. 1996; 348:423-428.159. Parker B.A., Capizzi J.A., Grimaldi A.S., et al. Effect of statins on skeletal musclefunction.

Circulation 2013; 127:96—103.160. Pasanen, M. K., Fredrikson, H., Neuvonen, P. J. and Niemi, M. (2007), DifferentEffects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin andRosuvastatin. Clinical Pharmacology & Therapeutics, 82: 726–733.161. Petersen P., Godtfredsen J., Boysen G., Placebo-controlled, Randomized trial ofwarfarin and aspirin for prevention of thromboembolic complications in chronic atrialfibrillation: The Copenhagen AFASAK Study.

The Lancet. 1989; 333(8631):175–179162. Pfeifer M., Begerow B., Minne H.W. Vitamin D and muscle function. OsteoporosisInternational 2002; 13:187-94163. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normalcreatine kinase levels. Ann Intern Med 2002; 137:581-5.144164. Phillips P.S., Phillips C.T., Sullivan M.J., et al. Statin myotoxicity is associated withchanges in the cardiopulmonary function.

Atherosclerosis 2004; 177:183-8.165. Pisters R., et al. «A novel user-friendly score (HAS-BLED) to assess 1-year risk ofmajor bleeding in patients with atrial fibrillation: the Euro Heart Survey». Chest. 2010;138(5):1093–100166. Pisters R., Lane D.A., Marin F. et al. Stroke and thromboembolism in atrialfibrillation. Circulation J. 2012; 76:2289-2304.167. Postmus I. et al. Pharmacogenetic meta-analysis of genome-wide association studiesof LDL cholesterol response to statins. Nature communications.

2014; 5.168. Raffaele De C., Steen H., Lars W., et al. Anticoagulants in heart disease: current statusand perspectives, European Heart Journal, 2007; 7(28):880–913169. Ramsey L. B. et al. The Clinical Pharmacogenetics Implementation ConsortiumGuideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update //ClinicalPharmacology & Therapeutics. 2014; 4(96):432-428170.

Rettie A.E., et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelicvariant of CYP2C9. Pharmacogenetics. 1994;4(1):39–42.171. Rieder M., Reiner A., Gage B. et al. Effect of VKORC1 haplotypes on transcriptionalregulation and warfarin dose. N. Engl. J. Med. 2005; 352: 2285—2293.172. Rosemary J., Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnicvariation and clinical significance. Current clinical pharmacology. 2007; 1(2):93-109.173.

Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarinresistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427 (6974): 537–41174. Rost S. et al. Novel mutations in the VKORC1 gene of wild rats and mice–a responseto 50 years of selection pressure by warfarin? Bmc Genetics. 2009; 1(10):1-9.175. Rubin P, Robert I. Douglas L. Braunwald's Heart Disease: A Textbook ofCardiovascular Medicine, 2-Volume Set: Expert Consult Premium Edition - EnhancedOnline Features and Print. — Philadelphia: Saunders, 2011.

ISBN 1-4377-2708-5.145176. Ruiz Maldonado J.M., et al. [A pilot study in a community pharmacy to determinethe efficiency and the effectiveness of statin prescriptions]. Aten Primaria. 2015May;47(5):294-300177. Saffitz JE (2006). «Connexins, conduction, and atrial fibrillation». N. Engl. J. Med.354 (25): 2712–4.DOI:10.1056/NEJMe068088. PMID 16790707.178. Sadowitz B., Maier K.

G., Gahtan V. Basic science review: Statin therapy-Part I: Thepleiotropic effects of statins in cardiovascular disease //Vascular and endovascularsurgery. – 2010. – Т. 44. – №. 4. – С. 241-251.179. Schuster H. The GALAXY Program an update on studies investigating efficacy andtolerability of rosuvastatin for reducing cardiovascular risk. Investigating cardiovascularrisk reduction - the Rosuvastatin GALAXY Programme Expert Rev. Cardiovasc.

Ther.2007; 5:177-193.180. Search Collaborative Group. SLCO1B1 variants and statin-induced myopathy - agenomewide study. N. Engl. J. Med. 2008; 8(359): 789-799.181. Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke eventswith atorvastatin in hypertensive patients who have average or lower-than-averagecholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - LipidLowering Arm (ASCOT-LLA): a multicenter randomized controlled trial Lancet.

2003;361:1149-1158.182. Sewright K.A., Clarkson P.M., Thompson P.D. Statin myopathy: incidence, riskfactors, and pathophysiology. Curr Atheroscler Rep. 2007; 9:389–396183. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease withpravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995; 333:1301-1307.184. Shepherd J., et al. "Pravastatin in elderly individuals at risk of vascular disease(PROSPER): a randomised controlled trial." The Lancet 360.9346 (2002): 1623-1630.185. Singer, DE, Albers, GW, Dalen, JE, et al.

Antithrombotic therapy in atrial fibrillation:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8thEdition). Chest 2008; 133:546-592.146186. Sohara H., Amitani S., Kurose M. et al. Atrial fibrillation activates platelets andcoagulation in a time-dependent manner: a study in patients with paroxysmal atrialfibrillation. J. Am. Coll. Cardiol. 1997;29: 106-112.187. Soliman Hamad M. A., Eekelen E., Agt T., Straten A. H.

Selfmanagement programimproves anticoagulation control and quality of life: a prospective randomized study. Eur.J. Cardiothorac. Surg. 2009; 35: 265—269.188. Spatz E.S., Canavan M.E., Desai M.M. From here to JUPITER: identifying newpatients for statin therapy using data from the 1999-2004 National Health and NutritionExamination Survey. Circulation: Cardiovascular Quality and Outcomes. 2009;2: 41-48.189. Stoddard M.F. Risk of thromboembolism in new onset or transient atrial fibrillation.Progr. Cardiovasc.

Dis. 1996; 39:69-80.190. Stroke in AF working group. Independent predictors of stroke in patients with atrialfibrillation: a systematic review. Neurology. 2007; 69:546–554.191. Stroes, E. S., et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiologyand management.